Clinical Trials Logo

Smoldering Plasma Cell Myeloma clinical trials

View clinical trials related to Smoldering Plasma Cell Myeloma.

Filter by:

NCT ID: NCT05312255 Recruiting - Plasma Cell Myeloma Clinical Trials

Non-chemotherapeutic Interventions for the Improvement of Quality of Life and Immune Function in Patients With Multiple Myeloma

Start date: June 28, 2022
Phase: N/A
Study type: Interventional

This clinical trial investigates the effect of non-chemotherapeutic interventions in patients with multiple myeloma. Non-chemotherapeutic interventions such as physical activity and nutritional interventions (e.g., modifications in diet) have been shown to positively affect the immune system and improve overall quality of life. Another purpose of this study is for researchers to learn how the addition of a beta-blocker (propranolol) to the standard treatment regimen in patients with newly diagnosed multiple myeloma affects immune response and quality of life. A study from the Mayo Clinic looked at multiple myeloma patients who were on a beta-blocker while undergoing chemotherapy and found that the use of a beta-blocker resulted in improved patient survival outcomes. Non-chemotherapeutic treatment options may help decrease symptoms and improve quality of life for patients with multiple myeloma.

NCT ID: NCT05288062 Active, not recruiting - Plasma Cell Myeloma Clinical Trials

Immunomodulatory Drugs (Lenalidomide With or Without Pomalidomide) in Combination With a Corticosteroid Drug (Dexamethasone) for the Treatment of Multiple Myeloma

Start date: March 22, 2022
Phase: Phase 2
Study type: Interventional

This phase II trial studies the effect of immunomodulatory drug(s) in combination with a corticosteroid drug in treating patients with multiple myeloma or smoldering multiple myeloma. Immunomodulatory drugs such as lenalidomide and pomalidomide work through a variety of mechanisms to affect the function of the immune system. They are widely used as treatment for multiple myeloma and remain the backbone of therapy for both newly diagnosed patients and patients that have multiple myeloma that has come back after treatment (relapsed). Corticosteroid drugs like dexamethasone are strong anti-inflammatory agents that are also widely used to treat patients with multiple myeloma. This study may help doctors find out how patients respond to one treatment cycle of immunomodulatory drug(s) in combination with dexamethasone. This may help doctors determine which combinations of drugs work best in treating patients with multiple myeloma or smoldering multiple myeloma.

NCT ID: NCT05136807 Recruiting - Clinical trials for Monoclonal Gammopathy of Undetermined Significance

Quality of Life in Patients With Asymptomatic Monoclonal Gammopathies

Start date: June 7, 2016
Phase:
Study type: Observational

This study examines the quality of life in patients with monoclonal gammopathy of unknown significance and smoldering multiple myeloma. Collecting quality of life information from patients may help doctors learn more about the most common symptoms and concerns patients with monoclonal gammopathy of unknown significance and smoldering multiple myeloma may have.

NCT ID: NCT05014646 Recruiting - Clinical trials for Smoldering Plasma Cell Myeloma

Leflunomide for the Treatment of High-Risk Smoldering Multiple Myeloma in African-American and European-American Patients

Start date: March 7, 2022
Phase: Phase 2
Study type: Interventional

This phase II trial studies the effects of leflunomide in treating African-American and European-American patients with high-risk smoldering multiple myeloma. Leflunomide is used to decrease the body's immune response and may delay the symptoms of multiple myeloma in patients of African-American and European decent.

NCT ID: NCT04776395 Recruiting - Clinical trials for Smoldering Plasma Cell Myeloma

Iberdomide Alone or in Combination With Dexamethasone for the Treatment of Intermediate- or High-Risk Smoldering Multiple Myeloma

Start date: August 1, 2021
Phase: Phase 2
Study type: Interventional

This phase II trial studies the effects of iberdomide when given alone or in combination with dexamethasone in treating intermediate or high-risk smoldering multiple myeloma patients. Immunotherapy with iberdomide may induce changes in body's immune system and may interfere with the ability of cancer cells to grow and spread. Dexamethasone is a synthetic steroid (similar to steroid hormones produced naturally in the adrenal gland), and is used with other drugs in the treatment of some types of cancer. Giving iberdomide with dexamethasone my improve time to progression to symptomatic myeloma with improved tolerability.

NCT ID: NCT04370483 Active, not recruiting - Clinical trials for Smoldering Plasma Cell Myeloma

Leflunomide for the Treatment of High-Risk Smoldering Multiple Myeloma

Start date: October 8, 2020
Phase: Early Phase 1
Study type: Interventional

This pilot trial studies how well leflunomide works for the treatment of patients with high-risk smoldering plasma cell myeloma, for the delay of disease progression. Anti-inflammatory drugs, such as leflunomide lower the body's immune response and are used with other drugs in the treatment of some types of cancer. The information learned from this study will help researchers to learn more about the anti-myeloma activity of leflunomide, and whether it may delay the onset of symptomatic multiple myeloma in patients with high-risk smoldering multiple myeloma.

NCT ID: NCT03952832 Withdrawn - Clinical trials for Smoldering Plasma Cell Myeloma

Leflunomide in Treating Patients With High-Risk Smoldering Multiple Myeloma

Start date: December 11, 2019
Phase: Phase 2
Study type: Interventional

This phase II trial studies how well leflunomide works in treating patients with high-risk smoldering multiple myeloma. Leflunomide may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth.

NCT ID: NCT03937635 Recruiting - Clinical trials for Smoldering Plasma Cell Myeloma

Lenalidomide, and Dexamethasone With or Without Daratumumab in Treating Patients With High-Risk Smoldering Myeloma

Start date: September 16, 2019
Phase: Phase 3
Study type: Interventional

This phase III trial studies how well lenalidomide and dexamethasone works with or without daratumumab in treating patients with high-risk smoldering myeloma. Drugs used in chemotherapy, such as lenalidomide and dexamethasone, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Immunotherapy with monoclonal antibodies, such as daratumumab, may induce changes in the body's immune system and may interfere with the ability of tumor cells to grow and spread. Giving lenalidomide and dexamethasone with daratumumab may work better in treating patients with smoldering myeloma.

NCT ID: NCT03631043 Active, not recruiting - Clinical trials for Smoldering Plasma Cell Myeloma

Personalized Vaccine in Treating Patients With Smoldering Multiple Myeloma

Start date: December 21, 2018
Phase: Early Phase 1
Study type: Interventional

This early phase I trial studies the side effects of personalized vaccine in treating patients with smoldering multiple myeloma. Vaccines made from a person's blood and bone marrow may help the body build an effective immune response to kill cancer cells.

NCT ID: NCT02960555 Active, not recruiting - Clinical trials for Smoldering Plasma Cell Myeloma

Isatuximab With or Without Lenalidomide in Patients With High Risk Smoldering Multiple Myeloma (ISAMAR)

Start date: February 8, 2017
Phase: Phase 2
Study type: Interventional

This is a multi-center, open label, phase II study designed to evaluate the efficacy of isatuximab with or without lenalidomide when given to patients with high risk smoldering multiple myeloma.